Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities

Published:2021-11-16 Issue:sup1 Volume:24 Page:34-41
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Choi Briana M.¹^ORCID,Abraham Rachel B.²,Halawah Hala³,Calamia Matthias⁴^ORCID,Obeng-Kusi Mavis¹,Alrawashdh Neda¹,Arku Daniel¹,Abraham Ivo¹⁵^ORCID

Affiliation:

1. Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA

2. Department of Community, Environment and Policy, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA

3. Al-Zaytoonah University of Jordan, Amman, Jordan

4. Faculty of Pharmacy, Utrecht University, Utrecht, The Netherlands

5. University of Arizona Cancer Center, Tucson, AZ, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.2007705

Reference29 articles.

1. Generalisability in economic evaluation studies in healthcare: a review and case studies

2. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer

3. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy;JAMA Dermatology;2024-06-01

2. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region;Expert Opinion on Biological Therapy;2023-07-26

3. Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective;Annals of Pharmacotherapy;2023-01-13

4. Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris;JAMA Dermatology;2022-09-01

5. Estimation of Value-Based Price for Five High-Technology Medical Devices Approved by a Regional Health Technology Assessment Committee in Italy;Cureus;2022-05-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3